Quantifying the Impoverishing Effects of Purchasing Medicines: A Cross-Country Comparison of the Affordability of Medicines in the Developing World
Background:
Increasing attention is being paid to the affordability of medicines in low- and middle-income countries (LICs and MICs) where medicines are often highly priced in relation to income levels. The impoverishing effect of medicine purchases can be estimated by determining pre- and postpayment incomes, which are then compared to a poverty line. Here we estimate the impoverishing effects of four medicines in 16 LICs and MICs using the impoverishment method as a metric of affordability.
Methods and Findings:
Affordability was assessed in terms of the proportion of the population being pushed below US$1.25 or US$2 per day poverty levels because of the purchase of medicines. The prices of salbutamol 100 mcg/dose inhaler, glibenclamide 5 mg cap/tab, atenolol 50 mg cap/tab, and amoxicillin 250 mg cap/tab were obtained from facility-based surveys undertaken using a standard measurement methodology. The World Bank's World Development Indicators provided household expenditure data and information on income distributions. In the countries studied, purchasing these medicines would impoverish large portions of the population (up to 86%). Originator brand products were less affordable than the lowest-priced generic equivalents. In the Philippines, for example, originator brand atenolol would push an additional 22% of the population below US$1.25 per day, whereas for the lowest priced generic equivalent this demographic shift is 7%. Given related prevalence figures, substantial numbers of people are affected by the unaffordability of medicines.
Conclusions:
Comparing medicine prices to available income in LICs and MICs shows that medicine purchases by individuals in those countries could lead to the impoverishment of large numbers of people. Action is needed to improve medicine affordability, such as promoting the use of quality assured, low-priced generics, and establishing health insurance systems.
: Please see later in the article for the Editors' Summary
Vyšlo v časopise:
Quantifying the Impoverishing Effects of Purchasing Medicines: A Cross-Country Comparison of the Affordability of Medicines in the Developing World. PLoS Med 7(8): e32767. doi:10.1371/journal.pmed.1000333
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.1000333
Souhrn
Background:
Increasing attention is being paid to the affordability of medicines in low- and middle-income countries (LICs and MICs) where medicines are often highly priced in relation to income levels. The impoverishing effect of medicine purchases can be estimated by determining pre- and postpayment incomes, which are then compared to a poverty line. Here we estimate the impoverishing effects of four medicines in 16 LICs and MICs using the impoverishment method as a metric of affordability.
Methods and Findings:
Affordability was assessed in terms of the proportion of the population being pushed below US$1.25 or US$2 per day poverty levels because of the purchase of medicines. The prices of salbutamol 100 mcg/dose inhaler, glibenclamide 5 mg cap/tab, atenolol 50 mg cap/tab, and amoxicillin 250 mg cap/tab were obtained from facility-based surveys undertaken using a standard measurement methodology. The World Bank's World Development Indicators provided household expenditure data and information on income distributions. In the countries studied, purchasing these medicines would impoverish large portions of the population (up to 86%). Originator brand products were less affordable than the lowest-priced generic equivalents. In the Philippines, for example, originator brand atenolol would push an additional 22% of the population below US$1.25 per day, whereas for the lowest priced generic equivalent this demographic shift is 7%. Given related prevalence figures, substantial numbers of people are affected by the unaffordability of medicines.
Conclusions:
Comparing medicine prices to available income in LICs and MICs shows that medicine purchases by individuals in those countries could lead to the impoverishment of large numbers of people. Action is needed to improve medicine affordability, such as promoting the use of quality assured, low-priced generics, and establishing health insurance systems.
: Please see later in the article for the Editors' Summary
Zdroje
1. World Health Organization 2000 Global comparative pharmaceutical expenditures with related reference information. Health Economics and Drugs EDM Series No. 3 Geneva World Health Organization
2. World Health Organization 2004 WHO medicines strategy 2004–2007 - countries at the core. Available: http://www.who.int/medicinedocs/collect/medicinedocs/pdf/s5416e/s5416e.pdf Accessed 28 April 2009
3. van DoorslaerE
O'DonnellO
Rannan-EliyaRP
SomanathanA
AdhikariSR
2006 Effect of payments for health care on poverty estimates in 11 countries in Asia: an analysis of household survey data. Lancet 368 1357 1364
4. CameronA
EwenM
Ross-DegnanD
BallD
LaingR
2009 Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet 373 240 249
5. DrorDM
PrekerAS
JakabM
2002 The role of communities in combating social exclusion.
DrorDM
PrekerAS
Social reinsurance - a new approach to sustainable community health financing Washington (D.C.); Geneva The World Bank Group and the International Labour Office
6. World Health Organization 2008 Access to medicines. Available: http://www.who.int/trade/glossary/story002/en/ Accessed 22 April 2009
7. United Nations 1948 The universal declaration of human rights, article 25. Available: http://www.un.org/Overview/rights.html#a25. Accessed 22 April 2009
8. United Nations 1966 International covenant on economic, social and cultural rights, article 12. Geneva. Available: http://www.unhchr.ch/html/menu3/b/a_cescr.htm. Accessed 22 April 2009
9. World Health Organization, Health Action International 2008 Measuring medicine prices, availability, affordability and price components – 2nd edition Geneva World Health Organization
10. NiënsLM
BrouwerWB
2009 Better measures of affordability required. Lancet 373 1081 author reply 1081–1082
11. NiënsLM
Van de PoelE
CameronA
EwenM
LaingR
2009 Practical measurement of affordability: an application to medicines Rotterdam Institute of Health Policy and Management, Erasmus University Working Paper W2009.02
12. HancockKE
1993 ‘Can pay? won't pay?’ or economic principles of ‘Affordability’. Urban Stud 30 127 145
13. KuttyNK
2005 A new measure of housing affordability: estimates and analytical results. Hous Policy Debate 16 113 142
14. BundorfMK
PaulyMV
2006 Is health insurance affordable for the uninsured? J Health Econ 25 650 673
15. ChenS
RavallionM
2008 The developing world is poorer than we thought, but no less successful in the fight against poverty Washington (D.C.) Development Research Group, The World Bank Group
16. The World Bank Group. Available: http://go.worldbank.org/C9GR27WRJ0. Accessed 10 January 2010
17. Health Action International. Medicine prices. Available: http://www.haiweb.org/medicineprices/. Accessed 5 March 2009
18. The World Bank Group. World development indicators. Available: http://publications.worldbank.org/WDI/. Accessed 12 March 2009
19. O'DonnellO
van DoorslaerE
WagstaffA
LindelowM
2008 Analyzing health equity using household survey data – A guide to techniques and their implementation Washington (D.C.) The World Bank Group
20. The Economist. The economist intelligence unit. Available: http://www.eiu.com/. Accessed 2 April 2009
21. The World Bank Group. Country groups. Available: http://go.worldbank.org/D7SN0B8YU0. Accessed 16 March 2009
22. FloresG
KrishnakumarJ
O'DonnellO
van DoorslaerE
2008 Coping with health-care costs: implications for the measurement of catastrophic expenditures and poverty. Health Econ 17 1393 1412
23. World Health Organization 2008 WHO model formulary. Available: http://www.who.int/selection_medicines/list/WMF2008.pdf. Accessed 27 August 2009
24. United Nations Development Program 2008 Human development report 2007/2008. Available: http://hdr.undp.org/en/media/HDR_20072008_Tables.pdf. Accessed 19 February 2009
25. LiptonM
RavaillonM
1994 Povert and policy.
BehrmanJ
SrinivasanTN
Handbook of development economics Amsterdam: Elsevier
26. World Health Organization 2004 Global burden of disease - 2004 update. Available: http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html. Accessed 12 February 2010
27. WaningB
KaplanW
KingAC
LawrenceDA
LeufkensHG
2009 Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases. Bull World Health Organ 87 520
28. World Health Organization 2006 Public health innovation and intellectual property rights. report of the commission on intellectual property rights, innovation, and public health Geneva World Health Organization
29. SeimL
2007 Thailand: government issues compulsory licences for HIV/AIDS drugs. HIV AIDS Policy Law Rev 12 28 29
30. FordN
WilsonD
Costa ChavesG
LotrowskaM
KijtiwatchakulK
2007 Sustaining access to antiretroviral therapy in the less-developed world: lessons from brazil and Thailand. AIDS (London) 21 S21 S29
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2010 Číslo 8
- Mobilní aplikace jako nová možnost v prevenci napadení klíštětem
- Hydroresponzivní krytí v epitelizační fázi hojení rány
- Vztah mezi statiny a rizikem vzniku nádorových onemocnění − metaanalýza
- Myasthenia gravis: kombinace chirurgie a farmakoterapie jako nejefektivnější modalita?
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
Najčítanejšie v tomto čísle
- Using Touchscreen Electronic Medical Record Systems to Support and Monitor National Scale-Up of Antiretroviral Therapy in Malawi
- Physical Activity Attenuates the Genetic Predisposition to Obesity in 20,000 Men and Women from EPIC-Norfolk Prospective Population Study
- Challenges in Developing Evidence-Based Recommendations Using the GRADE Approach: The Case of Mental, Neurological, and Substance Use Disorders
- Reducing Malaria Transmission in Africa: A Model-Based Evaluation of Intervention Strategies